Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, Salmenniemi U, Sengeloev H, Aljurf M, Helbig G, Kinsella F, Choi G, Reményi P, Snowden JA, Robin M, Lenhoff S, Mielke S, Passweg J, Broers AEC, Kröger N, Yegin ZA, Tan SM, Hayden PJ, McLornan DP, Yakoub-Agha I; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Chalandon Y, et al. Among authors: salmenniemi u. Am J Hematol. 2023 Jan;98(1):112-121. doi: 10.1002/ajh.26764. Epub 2022 Oct 31. Am J Hematol. 2023. PMID: 36266607 Free PMC article.
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT.
Gagelmann N, Eikema DJ, de Wreede LC, Rambaldi A, Iacobelli S, Koster L, Caillot D, Blaise D, Remémyi P, Bulabois CE, Passweg J, Leleu X, Zver S, Kobbe G, Ljungman P, Chevallier P, Ringhoffer M, Martin M, Salmenniemi U, Poiré X, Lenhoff S, Pioltelli P, Mordini N, Delforge M, Garderet L, Schönland S, Yakoub-Agha I, Kröger N. Gagelmann N, et al. Among authors: salmenniemi u. Bone Marrow Transplant. 2021 Jan;56(1):210-217. doi: 10.1038/s41409-020-01007-w. Epub 2020 Jul 24. Bone Marrow Transplant. 2021. PMID: 32710010
Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.
Onida F, Sbianchi G, Radujkovic A, Sockel K, Kröger N, Sierra J, Socié G, Cornelissen J, Poiré X, Raida L, Bourhis JH, Finke J, Passweg J, Salmenniemi U, Schouten HC, Beguin Y, Martin S, Deconinck E, Ganser A, Zver S, Lioure B, Rohini R, Koster L, Hayden P, Iacobelli S, Robin M, Yakoub-Agha I. Onida F, et al. Among authors: salmenniemi u. Bone Marrow Transplant. 2022 Jun;57(6):896-902. doi: 10.1038/s41409-021-01555-9. Epub 2022 Mar 29. Bone Marrow Transplant. 2022. PMID: 35352038 Free article.
Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT.
McLornan DP, Gras L, Martin I, Sirait T, Schroeder T, Blau IW, Kuball J, Byrne J, Collin M, Stadler M, Desmier D, Salmenniemi U, Jindra P, Mikhailova N, Lenhoff S, Rifón J, Robin M, Rovira M, Veelken H, Sadowska-Klasa A, Zecca M, Hayden PJ, Czerw T, Hernández-Boluda JC, Yakoub-Agha I. McLornan DP, et al. Among authors: salmenniemi u. Br J Haematol. 2022 Jul;198(1):209-213. doi: 10.1111/bjh.18219. Epub 2022 Apr 28. Br J Haematol. 2022. PMID: 35482558 No abstract available.
Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, Tholouli E, Byrne JL, Orchard K, Salmenniemi U, Hilgendorf I, Hunter H, Nicholson E, Bloor A, Snowden JA, Verbeek M, Clark A, Savani BN, Spyridonidis A, Nagler A, Mohty M. Duque-Afonso J, et al. Among authors: salmenniemi u. Bone Marrow Transplant. 2022 Aug;57(8):1269-1276. doi: 10.1038/s41409-022-01646-1. Epub 2022 May 14. Bone Marrow Transplant. 2022. PMID: 35568756 Free PMC article.
Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT.
Nagler A, Ngoya M, Galimard JE, Labopin M, Kröger N, Socié G, Gedde-Dahl T, Potter V, Schroeder T, Platzbecker U, Ganser A, Blaise D, Salmenniemi U, Maertens J, Craddock C, Labussière-Wallet H, Yakoub-Agha I, Savani B, Mohty M. Nagler A, et al. Among authors: salmenniemi u. Bone Marrow Transplant. 2022 Dec;57(12):1788-1796. doi: 10.1038/s41409-022-01825-0. Epub 2022 Sep 16. Bone Marrow Transplant. 2022. PMID: 36114249
Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).
Gavriilaki E, Labopin M, Sakellari I, Salmenniemi U, Yakoub-Agha I, Potter V, Berceanu A, Rambaldi A, Hilgendorf I, Kröger N, Mielke S, Zuckerman T, Sanz J, Busca A, Ozdogu H, Anagnostopoulos A, Savani B, Giebel S, Bazarbachi A, Spyridonidis A, Nagler A, Mohty M. Gavriilaki E, et al. Among authors: salmenniemi u. Bone Marrow Transplant. 2022 Dec;57(12):1803-1809. doi: 10.1038/s41409-022-01830-3. Epub 2022 Sep 22. Bone Marrow Transplant. 2022. PMID: 36138068
CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission.
Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Salmenniemi U, Mielke S, Chevallier P, Thérèse Rubio M, Balsat M, Pioltelli P, Menard AL, Socié G, Huynh A, Schaap N, Bermúdez Rodríguez A, Cornelissen JJ, Yakoub-Agha I, Aljurf M, Giebel S, Brissot E, Peric Z, Nagler A, Mohty M. Kharfan-Dabaja MA, et al. Among authors: salmenniemi u. Hemasphere. 2022 Oct 12;6(11):e788. doi: 10.1097/HS9.0000000000000788. eCollection 2022 Nov. Hemasphere. 2022. PMID: 36258923 Free PMC article.
Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT.
Nagler A, Ngoya M, Galimard JE, Labopin M, Kröger N, Socié G, Gedde-Dahl T, Potter V, Schroeder T, Platzbecker U, Ganser A, Blaise D, Salmenniemi U, Maertens J, Craddock C, Labussière-Wallet H, Yakoub-Agha I, Savani B, Mohty M. Nagler A, et al. Among authors: salmenniemi u. Bone Marrow Transplant. 2022 Dec;57(12):1856. doi: 10.1038/s41409-022-01853-w. Bone Marrow Transplant. 2022. PMID: 36280759 No abstract available.
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S, Labopin M, Schroeder T, Swoboda R, Maertens J, Bourhis JH, Grillo G, Salmenniemi U, Hilgendorf I, Kröger N, Poiré X, Cornelissen JJ, Arat M, Savani B, Spyridonidis A, Nagler A, Mohty M. Giebel S, et al. Among authors: salmenniemi u. Am J Hematol. 2023 Apr;98(4):580-587. doi: 10.1002/ajh.26825. Epub 2023 Jan 10. Am J Hematol. 2023. PMID: 36626592 Free article.
91 results